

# Loredana Cleris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1810611/publications.pdf>

Version: 2024-02-01

46  
papers

2,472  
citations

257450

24  
h-index

243625

44  
g-index

47  
all docs

47  
docs citations

47  
times ranked

3750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. <i>Cancer Letters</i> , 2002, 175, 17-25.	7.2	441
2	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. <i>Cancer Research</i> , 2006, 66, 11314-11322.	0.9	352
3	In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. <i>Journal of the National Cancer Institute</i> , 1999, 91, 163-168.	6.3	341
4	Growth-inhibitory effect of STI571 on cells transformed by theCOL1A1/PDGFB rearrangement. <i>International Journal of Cancer</i> , 2001, 92, 354-360.	5.1	114
5	Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. , 1996, 65, 491-497.		106
6	TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. <i>Oncogene</i> , 2011, 30, 3011-3023.	5.9	78
7	IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. <i>Oncogene</i> , 2010, 29, 3835-3844.	5.9	69
8	Inhibition of RET tyrosine kinase by SU5416. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 199-212.	2.5	68
9	Metallothionein 1G acts as an oncosuppressor in papillary thyroid carcinoma. <i>Laboratory Investigation</i> , 2008, 88, 474-481.	3.7	60
10	Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. <i>Experimental Hematology</i> , 2004, 32, 171-178.	0.4	48
11	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Cevinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2014, 28, 1861-1871.	7.2	48
12	Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of $\beta$ -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. <i>Cancer Research</i> , 2010, 70, 7253-7263.	0.9	45
13	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
14	Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. , 1999, 81, 829-834.		42
15	S100A11 Overexpression Contributes to the Malignant Phenotype of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1591-E1600.	3.6	40
16	AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. <i>Melanoma Research</i> , 2012, 22, 341-350.	1.2	38
17	The Anti- $\alpha$ -Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2006, 66, 1799-1808.	0.9	37
18	Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. <i>PLoS ONE</i> , 2013, 8, e61603.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. <i>British Journal of Cancer</i> , 2001, 84, 1528-1534.	6.4	33
20	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, 17, 1225-1240.	2.7	33
21	Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. <i>Blood</i> , 2010, 115, 2231-2240.	1.4	32
22	Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. <i>Blood</i> , 2004, 103, 2787-2794.	1.4	30
23	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1990-1996.	5.1	29
24	Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation. <i>Oncogene</i> , 2003, 22, 807-818.	5.9	28
25	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013, 27, 1677-1687.	7.2	26
26	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006, 34, 721-727.	0.4	25
27	Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. <i>European Journal of Cancer</i> , 2000, 36, 2411-2419.	2.8	22
28	Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. <i>Stem Cells</i> , 2016, 34, 2449-2460.	3.2	21
29	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. <i>Cells</i> , 2019, 8, 683.	4.1	21
30	Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 21, 329-36.	2.3	19
31	IFN- $\beta$ Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. <i>Cancer Research</i> , 2007, 67, 3269-3275.	0.9	18
32	Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. <i>Cancer Research</i> , 2002, 62, 6152-7.	0.9	18
33	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. <i>Cancer Letters</i> , 2017, 410, 201-211.	7.2	15
34	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 78.	8.6	15
35	Characterization of compound 584, an Abl kinase inhibitor with lasting effects. <i>Haematologica</i> , 2008, 93, 653-661.	3.5	14
36	Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. <i>Stem Cells</i> , 2007, 25, 252-261.	3.2	12

#	ARTICLE	IF	CITATIONS
37	Effect of imatinib on haematopoietic recovery following idarubicin exposure. <i>Leukemia</i> , 2003, 17, 298-304.	7.2	11
38	D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies. <i>PLoS ONE</i> , 2013, 8, e59691.	2.5	9
39	Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo. <i>British Journal of Cancer</i> , 1988, 57, 343-347.	6.4	8
40	Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2004, 32, 68-75.	0.4	7
41	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells. <i>Angiogenesis</i> , 2013, 16, 707-722.	7.2	5
42	Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors. <i>Frontiers in Pharmacology</i> , 2017, 8, 226.	3.5	5
43	Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 383-388.	4.2	4
44	Senescent Thyrocytes, Similarly to Thyroid Tumor Cells, Elicit M2-like Macrophage Polarization In Vivo. <i>Biology</i> , 2021, 10, 985.	2.8	3
45	Water-soluble derivatives of 4-(4-hydroxyphenyl) retinamide: synthesis and biological activity. <i>Chemical Biology and Drug Design</i> , 2016, 88, 608-614.	3.2	2
46	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, .	2.7	0